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Introduction
Tissue acquisition by means of endoscopic ultrasound (EUS)-
guided fine-needle aspiration (FNA) is the standard of care for
diagnosing pancreatic malignancy. Systematic reviews and
meta-analyses [1, 2] have reported pooled sensitivity of 86.8%
and 85%, respectively. However, reported sensitivity varies and
some studies that have used strict cytological criteria and
accounted for inadequate samples have documented less im-
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ABSTRACT
Background A novel fork-tip fine-needle biopsy (FNB) nee-
dle has recently been introduced for endoscopic ultrasound
(EUS)-guided sampling. The aim of this study was to com-
pare the performance of fork-tip FNB histology and stand-
ard fine-needle aspiration (FNA) cytology in the diagnosis
of solid pancreatic masses.
Methods A randomized crossover study was performed in
patients referred for EUS-guided sampling. Three passes
were taken with each needle in a randomized order. Only
samples reported as diagnostic of malignancy were consid-
ered positive. The primary end point was the sensitivity of
diagnosis of malignancy. Secondary end points included
the amount of sample obtained, ease of diagnosis, duration
of tissue sampling, pathologist viewing time, and cost.
Results 108 patients were recruited. Median age was 69
years (range 30–87) and 57 were male; 85.2% had a final
diagnosis of malignancy. There were statistically significant
differences in sensitivity (82% [95% confidence interval (CI)
72% to 89%] vs. 71% [95%CI 60% to 80%]), accuracy (84%
[95%CI 76% to 91%] vs. 75% [95%CI 66% to 83%]), propor-
tion graded as a straightforward diagnosis (69% [95%CI 60
% to 78%] vs. 51% [95%CI 41% to 61%]), and median pa-
thology viewing time (188 vs. 332 seconds) (P <0.001) be-
tween FNB and FNA needles, respectively. There was no sig-
nificant difference in cost between an FNB or FNA strategy.
Conclusion The diagnostic performance of the fork-tip FNB
needle was significantly better than that of FNA; it was
associated with ease of diagnosis, shorter pathological
viewing times, and was cost neutral.
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pressive diagnostic performance [3–5]. In an international sur-
vey, only one third of endosonographers reported a sensitivity
for the diagnosis of solid mass lesions of >80% [6]. Needle
size, aspiration technique (suction/no-suction, slow stylet
pull), and the use of rapid onsite evaluation (ROSE) [7] have all
been investigated as means of improving diagnostic perform-
ance, without consistent benefit. EUS-guided fine-needle biop-
sy (FNB) with acquisition of tissue cores for histological assess-
ment offers the theoretical benefit of preserved tissue architec-
ture, improved sample adequacy, and therefore better diagnos-
tic performance. However, the majority of studies with the first-
generation reverse bevel needle (ProCore; Cook Medical, Bloo-
mington, Indiana, USA) have found no diagnostic benefit [8, 9].
Recently, a new core biopsy needle with a novel fork tip
(SharkCore FNB needle; Medtronic, Watford, UK) has been in-
troduced. Initial case series have suggested improved diagnos-
tic performance compared with FNA [10, 11] and first-genera-
tion core biopsy [12] needles. Prospective randomized studies
to investigate this new fork-tip needle vs. FNA needles are lack-
ing. Therefore, the aim of our study was to address this ques-
tion in a randomized crossover study.
Methods
Study design and patient population
The study recruited consecutive patients attending for EUS-
guided tissue sampling of solid pancreatic masses in a tertiary
pancreatic cancer center between May 2017 and June 2018.
Written informed consent was obtained from all patients for
the procedure. The study was carried out in accordance with
the Declaration of Helsinki and was approved by the North
East-Newcastle and North Tyneside 1 Research Ethics Commit-
tee (reference 17/NE/001). The study is registered at Clinical-
Trials.gov (NCT03532347), and is reported according to the
Standards for Reporting Diagnostic Accuracy Studies (STARD)
and the Consolidated Standards of Reporting Trials (CONSORT)
statements (see the online-only Supplementary material).
Adult patients (≥18 years) with a suspicion of pancreatic
mass based on prior cross-sectional imaging were eligible. Ex-
clusion criteria included cystic lesions without a significant so-
lid component, and any contraindication to pancreatic biopsy.
The presence of a self-expandable metal stent in patients with
a mass in the head of the pancreas was an initial exclusion crite-
rion, but this was removed by protocol amendment part way
through the study.
EUS-guided sampling
All procedures were performed under conscious sedation using
combinations of intravenous midazolam and pethidine, with
standard cardiorespiratory monitoring. Pentax echoendo-
scopes (EG327OUK and EG3870UTX; Pentax, Slough, UK) and
Hitachi ultrasound workstations (Preirus; Hitachi Medical Sys-
tems, Wellingborough, UK) were used. A single Beacon EUS de-
livery device (Medtronic Ltd., Watford, UK) was used with 25-
gauge and 22-gauge needles for transduodenal and transgas-
tric biopsy, respectively. For all procedures, 10mL suction and
fanning were used. The needle was moved backward and for-
ward within the lesion for a minimum of 10 throws. Suction
was stopped prior to withdrawal of the needle.
Needles were used in a randomized order. Patients were ran-
domly allocated to an initial three passes with the FNA needle
(Beacon FNA needle; Medtronic) or FNB needle (SharkCore FNB
needle; Medtronic) and then crossed over to the other needle.
Randomization was via a computer-generated list of allocations
produced in advance of the study and referred to after partici-
pant recruitment. After the initial three passes, the first needle
was discarded and the other needle was affixed to the delivery
device, which remained attached to the echoendoscope, and a
further three passes were made. Procedures were timed using a
stopwatch.
Samples were expelled from the needles in a standardized
manner. The stylet was first introduced and then the needle
was flushed with a few milliliters of normal saline. For FNA, a
drop from the needle was expelled onto a glass slide and a sin-
gle spread slide was made from each pass. The remaining aspi-
rate was expelled into a container with approximately 5mL of
BD CytoRich Red Preservative solution (BD; Bioscience Health-
care, Nottingham, UK). The air-dried slides, including the draw
slide, were fixed in Reastain Quick Diff fix solution (Gamidor
Technical Services, Southmead Park UK) to be stained using
the Reastain Quick Diff stains. In the laboratory, any clots or mi-
crobiopsies present in the CytoRich solution were removed and
placed in formalin and subsequently embedded in paraffin. A
single 4-μm section was cut and stained with hematoxylin and
eosin (H&E).
For all specimens, the remaining CytoRich specimen was
processed for staining by SurePath Papanicolaou staining
method (Bioscience Healthcare).
All samples from the FNB needle were placed in a single con-
tainer of 10% neutral buffered formalin. Samples were subse-
quently embedded in paraffin. A single 4-μm section was cut
and stained with H&E.
Additional stains were performed at the discretion of the
pathologist if further information for diagnosis was required.
Follow-up
All procedures were performed as day cases. Patients were ob-
served in the endoscopy recovery area as per routine recovery
protocol until fully awake and allowed home if asymptomatic.
Patients were contacted by a research nurse 7 days after the
procedure to ascertain the occurrence of any post-procedure
adverse events. Serious adverse events were defined as compli-
cations resulting in a physician visit or an episode of hospitaliza-
tion or extension of an existing hospital stay, significant disabil-
ity or death [13].
Pathology
The FNA samples were reported by one of two specialist cyto-
pathologists and the FNB by one of two pancreatic histopathol-
ogists. The pathologists were blinded to the report of the other
sampling method. All samples were reported with a prose re-
port describing the findings, with an interpretation and final di-
agnostic category: inadequate, benign, atypical, suspicious of
malignancy or malignant. The pathologist timed microscope
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interpretation using a stopwatch (including for any subsequent
immunostaining); only the time spent examining slides was
measured. A novel, simple three-tier score to allow comparison
of cytology and histology samples with regard to amount of di-
agnostic material and ease of diagnosis was used (see Supple-
mentary material).
Definitions and end points
The primary end point was diagnostic performance of the fork-
tip FNB needle compared with the standard FNA needle. The
primary end point was assessed using “strict” criteria as fol-
lows; samples reported as benign, atypical, and suspicious
were categorized as negative for malignancy and only samples
reported as malignant were categorized as positive for malig-
nancy. For the purposes of the study, low grade malignant tu-
mors (i. e. gastrointestinal stromal tumors, lymphoma, and
neuroendocrine tumors) were considered malignant. Speci-
mens that contained inadequate material were not excluded
from primary analysis and were considered as negative for ma-
lignancy. A secondary “less strict” analysis was also performed
excluding inadequate samples and categorizing suspicious
samples as diagnostic of malignancy.
A conventional “malignancy” analysis was performed purely
for the differentiation of malignancy from benign (i. e. correct
classification as benign or malignant was the only require-
ment). A “specific diagnosis” analysis was also performed; for
this, a specific tissue diagnosis that matched the final diagnosis
was required. Diagnostic performance was expressed using
standard performance parameters including sensitivity, specifi-
city, and overall accuracy. Secondary end points were duration
of sampling time (in seconds), duration of pathologist viewing
time (in seconds), amount of diagnostic material, ease of diag-
nosis, and cost analysis.
The final gold standard diagnosis for malignancy required ei-
ther unequivocal malignant pathology obtained by EUS sam-
pling, surgical resection or alternative biopsy. For nonoperated
patients with nondiagnostic tissue sampling, clinical and radio-
logical disease progression consistent with malignancy at 6-
month follow-up was required.
Benign classification required nonmalignant and nonsuspi-
cious tissue sampling and follow-up of at least 6 months with a
consistent clinical picture and no evidence of malignancy on in-
terval imaging.
Statistical analysis
Sample size
The sample size was calculated in order to show a difference in
sensitivity for the diagnosis of malignancy of 14% between
groups based on prior data from our unit (92% FNB, 78% FNA).
The percentage of patients having discordant results for the
two needles was estimated to be 22%. Using a 5% significance
level and 80% power, we calculated that 86 malignant cases
were required and estimated that malignant cases would ac-
count for 85% of all recruited cases. It was also assumed that
there would be an attrition rate of 5% due to loss of patients
during follow-up.After inflating the sample size to account for
both factors, we calculated that 107 patients were required. To
allow for a balanced design the target sample size was set at
108.
Data analyses
Baseline characteristics of the patient population, pancreatic
mass lesions, technical details, and procedure outcomes were
summarized as means with standard deviation (SD) or medians
with interquartile range (IQR) for continuous data, and as fre-
quencies and proportions for categorical data. The data analy-
sis allowed for the fact that each patient had two results, and
that two outcomes from the same patient are likely to be
more similar than two results from different patients. The anal-
ysis also factored in that outcomes in the first period (i. e. first
needle used) may be different from those in the second period.
All analyses were performed using multilevel logistic regression
or multilevel linear regression (STATA version 15.1; StataCorp,
College Station, Texas, USA). Two-level models were used,
with individual results nested within patients. Fixed terms
were included in the model for the period (first or second nee-
dle) and the needle used (FNA or FNB), while patient was used
as a random factor.
An initial analysis examined whether the differences be-
tween needles varied depending on whether they were from
the first or second period (needle by period interaction) as this
could indicate a carryover effect from the first to second peri-
od. If this interaction was not statistically significant, the inter-
action term was omitted, and the differences between needles
were assessed using data from both periods.
Analysis of diagnostic performance, amount of material, and
ease of diagnosis was performed. For amount of material and
ease of diagnosis, two different outcomes were considered:
first, the proportion scored as 3, and second the proportion
scored as 2 or 3. Tissue sampling duration and pathology view-
ing time were compared. All tests were two-sided and P values
< 0.05 were considered statistically significant.
Cost analysis
The cost of an FNB sampling strategy was compared with an
FNA sampling strategy. The cost was based on the England
National Health Service (NHS) 2017/18 tariff for an EUS tissue
sampling procedure (€639). This tariff includes the cost of any
of the accessories used, pathological processing, and re-
porting. The standard NHS cost was €187 for the FNA needle
and €263 for the fork-tip needle. To better reflect the cost of
needle choice to the health economy for the purposes of the
study, the “cost” of the procedure was assumed to be the NHS
tariff plus the cost of needle.
If a nondiagnostic result was obtained, it was assumed that a
single repeat procedure would be performed for that patient
using the same type of needle. Bootstrap methods were used
to obtain the confidence interval (CI) for the cost difference be-
tween needles; 100 bootstrap samples were used in the calcu-
lations.
456 Oppong Kofi W et al. Fork-tip FNB vs FNA in EUS-guided sampling of solid pancreatic masses… Endoscopy 2020; 52: 454–461
Original article
Results
A total of 171 patients were assessed for eligibility, 63 were ex-
cluded, and 108 (57 men, 51 women) with a median age of 69
years (range 30–87) were randomized (▶Fig. 1). Five patients
had a self-expandable metal stent in situ. Lesion characteristics
and final diagnoses are shown in ▶Table 1. ▶Table2 shows the
pathological diagnostic category. There was no difference be-
tween the FNB and FNA needles in the proportion of malignant
cases reported as unsatisfactory (3.3% vs 4.3%, respectively);
however, there was a difference in the proportion of malignant
cases categorized as suspicious (6.5% vs. 18.5%, respectively).
Diagnostic performance
The results (▶Table3) suggested that for all diagnostic out-
comes, there was no significant needle by period interaction.
Therefore, the needle effect was quantified using the data
from both periods combined.
There was a significant difference in diagnostic performance
between the needles. Sensitivity for FNB was 82% (95%CI 72%
to 89%) compared with 71% (95%CI 60% to 80%) for FNA; the
odds of detecting a malignancy with an FNB needle were >3
times higher than the odds for an FNA needle (odds ratio [OR]
3.23, 95%CI 1.12 to 9.38).
The needles were found to vary significantly in terms of ac-
curacy for specific diagnosis. Accuracy was 79% (95%CI 70% to
86%) for FNB compared with 64% (95%CI 54% to 73%) for FNA.
The odds of an accurate specific diagnosis were >4 times higher
with the FNB needle compared with the FNA needle (OR 4.79,
95%CI 1.67 to 13.7).
Analysis using less strict criteria
There was no significant difference in diagnostic performance
for malignancy or specific diagnosis when the “less strict” crite-
ria were used (Table1 s).
Duration of sampling and pathology viewing
▶Table 4 summarizes the results. The sampling time was found
to be significantly shorter for the FNB needle compared with
the FNA needle: mean 710 (SD 171) seconds vs. 759 (SD 144)
seconds (P=0.001). Pathology viewing times were also signi-
ficantly shorter for FNB compared with FNA needles: median
188 seconds (IQR 56–330) vs. 332 seconds (IQR 212–411) (P
<0.001).
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Assessed for eligibility (n = 171)
Randomized (n = 108)
Group 1
FNA needle first 
then FNB
n = 55; 22 g = 22, 
25 g = 33
Group 2
FNB needle first 
then FNA
n = 53; 22 g = 21, 
25 g = 32
Group 1
Lost to follow-up 
(n = 0)
Group 2
Lost to follow-up 
(n = 0)
Group 1
Analyzed 
(n = 55)
Group 2
Analyzed 
(n = 53)
Excluded (n = 63)
▪Declined to participate (n = 48)
▪No mass on EUS (n = 10)
▪Predominantly cystic lesion (n = 2)
▪Biliary metal stent in situ (n = 1)
▪Failed intubation (n = 1)
▪Large hiatus hernia prevented passage
 of echoendoscope (n = 1)
▶ Fig. 1 CONSORT study flow diagram. Enrollment and outcomes.
CONSORT, Consolidated Standards of Reporting Trials; FNA,
fine-needle aspiration; FNB, fine-needle biopsy.
▶Table 1 Lesion characteristics and final diagnosis.
Cases, n 108
Size of mass, median (IQR), mm 25 (19–34.5)
Location, n (%)
▪ Head/uncinate 62 (57.4)
▪ Neck 12 (11.1)
▪ Body 21 (19.4)
▪ Tail 13 (12.0)
Diagnosis, n (%)
Malignant 92 (85.2)
▪ Pancreatic ductal adenocarcinoma 69 (63.9)
▪ Neuroendocrine 14 (12.9)
▪ Metastatic renal cell carcinoma  4 (3.7)
▪ Lymphoma  2 (1.9)
▪ Cholangiocarcinoma  1 (0.92)
▪ Solid pseudopapillary neoplasm  1 (0.92)
▪ Metastatic breast adenocarcinoma  1 (0.92)
Benign 16 (14.8)
▪ Pancreatitis  9 (8.3)
▪ Heterotopic spleen  2 (1.9)
▪ Autoimmune pancreatitis  2 (1.9)
▪ Benign peripheral nerve tumour  1 (0.92)
▪ Unspecified  2 (1.9)
IQR, interquartile range.
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Amount of material, ease of diagnosis, and cost
The results for amount of material and ease of diagnosis are
summarized in ▶Table 5. A significantly higher proportion of
FNB cases were categorized as 3 (abundant for diagnosis): 58%
(95%CI 48% to 68%) vs. 44% (95%CI 35% to 54%) for FNA; how-
ever, this was associated with a significant needle by period in-
teraction. There was no difference when only data from the first
period were analyzed. For ease of diagnosis, a significantly
higher proportion of FNB cases were graded as 3 (straightfor-
ward diagnosis): 69% (95%CI 60% to 78%) vs. 51% (95%CI 41
% to 61%) for FNA. There was no significant difference in cost:
mean €1044 (SD 330) vs. €1033 (SD359) for FNB vs. FNA,
respectively. The mean difference was 12 (95%CI–55 to 95; P
=0.74).
Adverse events
Serious adverse events occurred in four patients within 7 days
(3.7%): two developed cholangitis (one of whom underwent
endoscopic retrograde cholangiopancreatography immediately
following EUS tissue sampling, and the other had a pre-existing
plastic biliary stent), one patient developed pancreatitis, and
one patient was hospitalized for 24 hours with severe abdomi-
nal pain.
Discussion
In this prospective, randomized, crossover study comparing the
fork-tip FNB and FNA needles in the sampling of solid pancreat-
ic masses, the FNB needle was more sensitive than the FNA nee-
▶Table 2 Pathological classification of samples.
Final diagnosis Unsatisfactory, n (%) Benign, n (%) Atypical, n (%) Suspicious, n (%) Malignant, n (%)
Malignant (n =92)
▪ FNB 3 (3.3) 2 (2.2) 6 (6.5) 6 (6.5) 75 (81.5)
▪ FNA 4 (4.3) 0 6 (6.5) 17 (18.5) 65 (70.7)
Benign (n =16)
▪ FNB 6 (37.5) 9 (56.2) 1 (6.2) 0 0
▪ FNA 5 (31.2) 7(43.7) 4 (25.0) 0 0
FNB, fine-needle biopsy; FNA, fine-needle aspiration.
▶Table 3 Diagnostic performance.
Outcome FNB FNA NxP
Interaction1
Effect of needle type
n/N % (95%CI) n/N % (95%CI) P value OR (95%CI)2 P value
Diagnosis of malignancy
▪ Accuracy 91/108 84 (76 to 91) 81/108 75 (66 to 83) 0.26 3.41
(1.12 to 10.4)
0.03
▪ Sensitivity 75/92 82 (72 to 89) 65/92 71 (60 to 80) 0.25 3.23
(1.12 to 9.38)
0.03
▪ Specificity 16/16 100 (79 to 100) 16/16 100 (79 to 100) – – –
▪ Positive predictive
value
75/75 100 (94 to 100) 65/65 100 (94 to 100) – – –
▪ Negative predictive
value
16/33 48 (31 to 66) 16/43 37 (22 to 53) 0.78 1.62
(0.64 to 4.10)
0.31
Specific diagnosis
▪ Accuracy 85/108 79 (70 to 86) 69/108 64 (54 to 73) 0.13 4.79
(1.67 to 13.7)
0.004
▪ Accuracy3 10/16 63 (35 to 85) 4/16 25 (7 to 52) – – –
FNB, fine-needle biopsy; FNA, fine-needle aspiration; NxP, needle by period; CI, confidence interval; OR, odds ratio.
1 Analysis to examine whether the differences between needles varied depending on whether they were used first or second.
2 OR calculated as odds for FNB relative to odds for FNA.
3 Analysis based on patients with a benign final diagnosis only.
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dle for the diagnosis of pancreatic malignancy (82% vs. 71%)
when using strict criteria. Additionally, FNB had significantly
shorter sampling and pathology viewing times, as well as great-
er ease of diagnosis reported by the pathologists. Under “less
strict” criteria, with suspicious samples categorized as diagnos-
tic of malignancy, the difference in diagnostic performance was
eliminated. However, a suspicious diagnosis is not acceptable
by most oncologists for initiation of chemotherapy and such
patients would not be eligible for recruitment into chemother-
apy trials.
EUS core biopsy needles have been designed to provide lar-
ger tissue samples with preserved tissue architecture that are
adequate for histological assessment. If achieved, this would
enable speedier, more accurate diagnosis, in addition to the po-
tential to conduct the more detailed histological subtyping and
genetic analysis of tumors required for personalized therapies.
Histological assessment should also facilitate the definitive di-
agnosis of benign conditions such as autoimmune pancreatitis
and chronic pancreatitis, which are challenging to make with
FNA.
The reverse bevel needle was the first widely used core biop-
sy needle; however, this has not shown unequivocal superiority
to FNA. A recent large prospective study [14] reported signifi-
cantly higher diagnostic yield with the reverse bevel needle
compared with FNA for pancreatic lesions; however, it is un-
clear whether this equated to better diagnostic accuracy or
rather more frequent diagnostic histological samples. In an ear-
lier study by Vanbiervliet et al., in addition to finding no differ-
ence in diagnostic performance, the authors reported better
overall sample quality with the FNA needle [15]. Two meta-ana-
lyses [8, 16] reported no significant difference in sensitivity or
acquisition of cores, while another [17] reported the core nee-
dles to have better specimen adequacy and diagnostic accura-
cy.
The SharkCore needle has a fork tip, opposing bevel design
with six cutting surfaces designed to acquire architecturally in-
tact tissue and minimize tissue disruption. Initial retrospective
studies documented high pathological yield with fewer passes
[10, 11] and the needle significantly outperformed the reverse
bevel with an adjusted OR of 7.93 [12]. A further retrospective
study found no difference in diagnostic performance between
the fork-tip needle and FNA needle, although the fork-tip nee-
dle yielded a significantly higher proportion of tissue that was
adequate for histological evaluation and ancillary diagnostic
techniques [18]. A recent multicenter prospective study using
the 25-gauge fork-tip needle for sampling solid pancreatic mas-
ses reported the presence of cores in 67% of samples [19]. In a
large retrospective study of 3020 patients, 71.3% of whom
were undergoing sampling of a pancreatic mass using FNA or
second-generation core biopsy needles (either Franseen–Ac-
quire, Boston Scientific Corp – or fork-tip), the median number
of passes required for diagnostic adequacy on ROSE was signif-
icantly lower for FNB compared with FNA, and diagnostic yield
on cell block was superior with FNB [20]. The superior perform-
ance of FNB over FNA was observed for both pancreatic and
nonpancreatic lesions. A multicenter retrospective study of
22-gauge fork-tip and 22-gauge FNA needles in patients with
solid pancreatic mass lesions found no significant difference in
diagnostic performance but a significantly reduced number of
passes to obtain diagnostic tissue [21]; ROSE was available for
all procedures in this study. Another retrospective study of pri-
marily pancreas and gut wall lesions without on-site cytopa-
thology also reported fewer needle passes with the fork-tip
needle [22]; there was, again, no significant difference in sensi-
tivity (fork-tip 89.9% vs. FNA 81.0%). The diagnostic perform-
ance of Franseen and fork-tip needles appears to be similar; a
recent randomized trial [23] found no significant difference be-
tween the two needles in tissue yield, with >90% of diagnostic
cell blocks.
Conventionally, the diagnostic performance of EUS tissue
sampling in pancreatic masses is considered in a binary manner
– cancer/noncancer. This reflects the clinical scenario in which
the pre-test probability of malignancy is high, and a diagnosis
of malignancy will trigger major surgery and/or chemotherapy.
However, a significant minority of cases (15% in the present
study) will be benign and a definitive histological diagnosis in
this context is of value. First, by enhancing the benign diagnosis
beyond one of just “nonmalignant,” confidence in the accuracy
▶Table 4 Sampling time and pathology viewing time.
Outcome FNB FNA NxP
interaction1
P value
Effect of needle type
Mean/Ratio
(95%CI)
P value
Sampling time, seconds n =108 Mean 710
(SD 171)
n =1062 Mean 759
(SD 144)
0.94 Mean–49
(–79 to –19)3
0.001
Pathology viewing time,
seconds
n =904 Median 188
(IQR 56–330)
n =895 Median 332
(IQR 212 –
411)
0.30 Ratio 0.49
(0.41 to 0.60)6
<0.001
FNB, fine-needle biopsy; FNA, fine-needle aspiration; NxP, needle by period; CI, confidence interval; IQR, interquartile range.
1 Analysis to examine whether the differences between needles varied depending on whether they were used first or second.
2 2 patients omitted from analysis as data unavailable.
3 Mean difference calculated as values for FNB minus values for FNA.
4 18 patients omitted from analysis.
5 19 patients omitted from analysis.
6 Ratio calculated as values for FNB divided by values for FNA.
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of the diagnosis is increased, thereby lessening the likelihood of
repeat sampling or inappropriate surgery. Second, a specific
histological diagnosis (e. g. autoimmune pancreatitis) will en-
sure appropriate therapy is initiated promptly.
This study therefore also reported diagnostic performance
in terms of requiring a specific tissue diagnosis (malignant or
benign) that matched the final diagnosis. Using this threshold,
a benign case (e. g. chronic pancreatitis) where the pathology
report stated benign/noncancer without establishing a diagno-
sis of chronic pancreatitis would be classified as inaccurate. Use
of this higher threshold resulted in an even greater difference in
diagnostic performance between the needles, with an OR of
4.79.
The results reflect the twin benefits of greater amount of tis-
sue and preserved tissue architecture with the FNB needle.
Sampling time was also significantly shorter, and reflects the
differences in in-room preparation; FNB samples were expelled
directly into formaldehyde whereas for each FNA pass, a slide
was prepared and the remaining material expelled into a con-
tainer. However, though statistically significant, this small dif-
ference in sampling time is unlikely to be clinically relevant.
The strengths of the present study include its prospective,
randomized, crossover design and the blinding of the reporting
pathologists to the results with the paired needle. Potential
weaknesses include the inability to blind the endosonographers
to the needle type; however, adherence to strict protocols in
terms of number of passes, throws within the lesion, and use
of the fanning technique should have mitigated this bias. The
use of separate histopathologists and cytopathologists is an-
other possible weakness as this prevented blinding to the nee-
dle type. However, both sets of pathologists had extensive ex-
pertise in the reporting of pancreatic histology and cytology,
respectively, and due to the very different nature of the patho-
logical processing it would have been impossible for patholo-
gists to be blinded to the nature of the sample they were re-
porting. The different processing techniques of the samples
does raise the possibility that this, and not only the needle,
was a factor in the data differences identified; however, any
clots or microbiopsies obtained with the FNA needle were pro-
cessed in the same way as samples from the FNB needle. Addi-
tionally, the amount of material and ease of diagnosis were as-
▶Table 5 Tissue amount and ease of diagnosis.
Outcome FNB FNA NxP
interaction1
Effect of needle type
n/N % (95%CI) n/N % (95%CI) P value OR (95%CI)2 P value
Amount of material classification
▪ Too scanty for diagnosis – 1 11 /108 10 (5 to 17) 18/108 17 (10 to 25)
▪ Sufficient for diagnosis – 2 34/108 31 (23 to 41) 42/108 39 (30 to 49)
▪ Abundant for diagnosis–3 63 /108 58 (48 to 68) 48 /108 44 (35 to 54)
Statistical comparison
▪ Proportion graded 3 63 /108 58 (48 to 68) 48 /108 44 (35 to 54) 0.01 2.17 (1.12 to
4.22)
0.02
▪ Proportion graded 33 27 /53 51 (37 to 65) 31 /55 56 (42 to 70) - 0.75 (0.27 to
2.06)
0.57
▪ Proportion graded 2 or 3 97 /108 90 (83 to 95) 90 /108 83 (75 to 90) 0.61 2.47 (0.84 to
7.25)
0.10
Ease of diagnosis classification
▪ Challenging/impossible–1 9 /108 8 (4 to 15) 12 /108 11 (6 to 19)
▪ Some difficulty–2 24 /108 22 (15 to 31) 41 /108 38 (29 to 48)
▪ Straightforward–3 75 /108 69 (60 to 78) 55 /108 51 (41 to 61)
Statistical comparison
▪ Proportion graded 3 75 /108 69 (60 to 78) 55 /108 51 (41 to 61) 0.17 3.48 (1.60 to
7.59)
0.002
▪ Proportion graded 2 or 3 99 /108 92 (85 to 96) 96 /108 89 (82 to 94) 0.87 1.62 (0.52 to
5.09)
0.41
FNB, fine-needle biopsy; FNA, fine-needle aspiration; NxP, needle by period; CI, confidence interval; OR, odds ratio.
1 Analysis to examine whether the differences between needles varied depending on whether they were used first or second.
2 OR given as odds for FNB relative to odds for FNA.
3 Results based on data from first period only.
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sessed using a novel nonvalidated scoring system, as existing
scoring systems were not suitable for this purpose.
In conclusion, we have demonstrated in a prospective ran-
domized study that the EUS fork-tip biopsy needle yielding a
histology specimen delivers substantially better diagnostic per-
formance, better sample amount, ease of reporting, and short-
er sampling and pathological viewing times than a standard
FNA needle yielding a cytology specimen, and this strategy
was cost neutral. This finding provides the first prospective evi-
dence to support the contention that such EUS core biopsy nee-
dles should be regarded as the standard of care for tissue acqui-
sition from solid pancreatic masses.
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